AstraZeneca Guards Nexium Patent, Takes Teva, Cipla To New Jersey Court
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - AstraZeneca, the maker of world's second largest selling drug brand Nexium (esomperazole) is going all out to protect the patent covering its popular anti-ulcer medicine
You may also be interested in...
Ranbaxy-AstraZeneca Pact Part Of Indian Drug Maker Trend
The patent-dispute settlement Ranbaxy Pharmaceuticals reached with AstraZeneca reflects a new Indian trend beyond the business of making generics. The settlement terms include Ranbaxy selling AstraZeneca's Nexium (esomeprazole) when the first of several patents expires in 2014. Like other Indian drug makers, Ranbaxy is expanding beyond the generics market to improve its research and development capabilities and make a dent in the branded drugs market. Ranbaxy plans to split its generics and branded efforts this summer, a move being taken by several Indian competitors with similar plans. (Click here for more
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).